Common anaerobic treatability of pharmaceutical and yeast industry wastewater

B. Gulmez*, I. Ozturk, K. Alp, O. A. Arikan

*Corresponding author for this work

Research output: Contribution to journalConference articlepeer-review

12 Citations (Scopus)

Abstract

The purpose of this study is to demonstrate the feasibility of anaerobic treatment of pharmaceutical and baker's yeast industry effluents in a joint treatment system. Anaerobic treatability studies have been performed in a lab-scale upflow anaerobic sludge blanket reactor (UASBR). The experimental study has been carried out for 333 days. The influent COD's during the experimental study were about 10,000 mg/l. Pharmaceutical wastewater has a 5% of inhibition on the COD removals at the dilution rate of 1/100 or more in the joint anaerobic treatment with baker's yeast industry effluents. Maximum inhibition of 10% on the average was observed when the system was characterized with acclimation periods. The study has shown that, following the solvent extraction with pre-aeration process, a common anaerobic treatment can be applied to baker's yeast industry wastewater and to pharmaceutical industry effluents.

Original languageEnglish
Pages (from-to)37-44
Number of pages8
JournalWater Science and Technology
Volume38
Issue number4-5 -5 pt 4
DOIs
Publication statusPublished - 1998
EventProceedings of the 1998 19th Biennial Conference of the International Association on Water Quality. Part 1 (of 9) - Vancouver, Can
Duration: 21 Jun 199826 Jun 1998

Keywords

  • Acclimation
  • Anaerobic treatment
  • Baker's yeast
  • Industry effluents
  • Inhibition
  • Pharmaceutical industry effluents

Fingerprint

Dive into the research topics of 'Common anaerobic treatability of pharmaceutical and yeast industry wastewater'. Together they form a unique fingerprint.

Cite this